Sungwon Lim, Ph.D.
Veterinary oncologists managing canine lymphoma face decisions that are equal parts clinical and economic: which drugs to choose, when to switch protocols, and how to communicate value to clients investing in their pet's care. As atypical and harder-to-predict B-cell presentations become more frequently recognized in practice, the need for patient-specific decision support has grown alongside the conversation about treatment economics.
In this presentation, Dr. Sungwon Lim, CEO and Co-Founder of ImpriMed, will share an updated view of how AI-guided treatment selection is influencing veterinary oncology practice. Drawing on ImpriMed's peer-reviewed clinical research and a new retrospective analysis examining the relationship between AI-predicted drug rankings and treatment economics, Dr. Lim will explore what the data reveals about clinical impact, cost-effectiveness, and the evolving standard of care.
The session will include comparative analysis of patient groups with high versus low alignment between predicted and administered treatments, discussion of where AI predictions fit within the broader diagnostic workflow, and a look at where ImpriMed's research is heading next.
